Skip to main content

Table 2 Registry site characteristics by anti-fibrotic use and by specific medication

From: Patient and site characteristics associated with pirfenidone and nintedanib use in the United States; an analysis of idiopathic pulmonary fibrosis patients enrolled in the Pulmonary Fibrosis Foundation Patient Registry

 

IPF patients, n = 1218

Using an anti-fibrotic, n = 703

Characteristic: count, mean (SD) or Frequency (%)

No anti-fibrotic use (n = 487)

Anti-fibrotic use (n = 740)

Nintedanib (n = 312)

Pirfenidone (n = 391)

Site-level Characteristics

 Region: South

173 (36.2)

332 (44.9)

153 (49.0)

161 (41.2)

  Northeast

96 (20.1)

172 (23.2)

73 (23.4)

91 (23.3)

  Midwest

97 (20.3)

154 (20.8)

49 (15.7)

99 (25.3)

  West

112 (23.4)

82 (11.8)

37 (11.9)

40 (10.2)

 Average UV index

5.9 (1.1)

5.9 (1.1)

6.0 (1.1)

5.9 (1.1)

 Maximum UV index

9.4 (1.0)

9.4 (1.0)

9.5 (1.1)

9.4 (1.0)

 Clinical trial experience – none

59 (12.7)

149 (20.1)

71 (23.1)

72 (18.9)

  Pirfenidone only

118 (25.5)

185 (25.5)

69 (22.5)

105 (27.5)

  Nintedanib only

20 (4.3)

22 (3.0)

12 (3.9)

8 (2.1)

  Both pirfenidone and nintedanib

265 (57.4)

369 (50.1)

155 (50.5)

197 (51.6)

 Participation in any trial (versus none)

403 (87.2)

576 (79.5)

236 (76.9)

310 (81.2)

  1. Abbreviations: Idiopathic Pulmonary Fibrosis (IPF); standard deviation (SD); ultraviolet (UV)